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South Africa (SA) has the largest national antiretroviral therapy 
(ART) programme in the world and is one of the countries with 
a high HIV prevalence.[1] Response to ART depends on various 
factors, such as gender, age, psychosocial support and disease stage 
on initiation.[2,3] The main outcomes of the ART programme are 
improved quality of life and reduced mortality.[4,5]
As a result of positive outcomes of ART programmes globally there 
have been several initiatives for rapid scale-up of ART in resource-
limited countries, including SA. Scaling up of ART in SA has meant 
an increase in the number of patients on ART and an increased 
workload for ART service providers. The number of patients who 
need ART will continue to increase, as the eligibility criteria for 
ART are continually reviewed to be in line with World Health 
Organization (WHO) guidelines and up-to-date research findings.[6]
The increased workload on health providers resulting from programme 
scale-up may result in poor programme outcomes.[1,7] While the ART 
programme is expanding in SA, it is therefore important to monitor the 
programme on a long-term basis by following cohort outcomes.
Objectives
To establish the number of patients who remained alive on ART after 5 
years of treatment and identify patient-related factors that contributed 
to the outcome of each indicator. The outcomes measured were 
retention in care, immunity gain and viral suppression. Evaluation 
of the outcome measures provides an important means of assessing 
ART programmes and facilitates development of optimal models of 
care in resource-limited settings.[8]
Methods
Study setting and inclusion criteria
The study took place in Tshwane district, Gauteng Province, SA. 
Five facilities participated, and the basis of selection was that they 
were initiating patients on ART in January 2007 and already had an 
electronic database. A SOZO database, which has records of all patients 
on ART in the participating facilities, was used as a data source.
Routine HIV care and clinic visits
Patients are referred to the ART programme when they are eligible 
for highly active antiretroviral therapy (HAART), which at the time 
of the study was when they have a CD4 count <200 cells/µL or 
met the other criteria for ART initiation.[9] (The SA ART initiation 
eligibility criteria recently changed to a CD4 count of 350 instead of 
200 cells/µL.) Once patients are initiated on HAART they visit the 
clinic every month to collect medication. A CD4 count is one of the 
tests done on baseline, and then routine blood tests, including CD4 
count and viral load (VL), are done after 6 months. Thereafter these 
are repeated annually from the date of initiation.
Outcome definitions
Adverse outcomes combined death, loss to follow-up, default and 
stopping treatment. Loss to follow-up was defined as patients who 
had not collected their medication for >90 days. Baseline blood tests 
(CD4 count) were those done before the patient started ART. The VL 
was considered to be suppressed if it was <400 copies/mL at 6 months 
and at the end of 60 months of treatment. Immunological response 
was measured as the CD4 count change from baseline.[9]
Design
A retrospective analytical cohort study design was used. The cohort 
consisted of all patients who had started ART between January and 
March 2007. These patients had completed 60 months (5 years) on 
treatment at the end of March 2012.
Sampling
It has been reported that non-retention of patients on ART in the clinics 
of SA and the sub-Saharan region ranges from 30% to 40%.[1,4,10] Retention 
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rates are usually reported over periods of 2  - 
3 years, and rates would be expected to be 
higher over the longer term. Assuming a rate 
of 40 - 50% for the purposes of sample size 
calculations, 45% was used as a non-retention 
rate. A margin of error of 5% was used at a 
95% compliance level, which led to the sample 
size of 381 records. Simple random sampling 
was done using Excel commands, where all 
1 044 patient records from five facilities were 
listed on one Excel spreadsheet and random 
selection of 381 records was made.
Statistical analysis
Summary statistics were used for gender and 
age at initiation, and medians to describe 
CD4 counts at baseline and at follow-up. 
Patient ages were categorised into four 
groups (Table 1), and a χ2 test was generated 
to analyse CD4 count in relation to age. To 
examine the impact of gender on CD4 count 
change, a simple linear regression test was 
performed.
Adverse outcomes, i.e. death, default, loss 
to follow-up or stopping ART, were com-
bined because of the small numbers of each 
outcome. Multivariate logistic regression 
was performed to determine the effect of 
gender on adverse outcomes, and Pearson’s 
χ2 test to examine the effect of age and 
baseline CD4 count on adverse outcomes. 
Logistic regression analysis was performed 
to determine the effect of gender, age and 
CD4 count on the adverse outcomes.
CD4 counts at baseline and 6 months 
were compared using a paired t-test. Linear 
regression analysis was used to examine the 
effect of gender, age and baseline CD4 count 
on changes in CD4 counts at 6 months and 
60 months, and logistic regression analysis to 
determine effects of gender and age on VL at 
6 months and 60 months.
Results
Baseline characteristics
A total of 381 patients were randomised 
from 1 044 patients initiated on ART 
between January and March 2007 at the five 
facilities in Tshwane district that participated 
in the study. Of the 381 patients, 251 (65.9%) 
were females and 130 (34.1%) males. The 
mean age at which ART was started was 35 
years, and the mean baseline CD4 count was 
126  cells/µL. Only 60 records had baseline 
and follow-up CD4 counts, and those 
were the ones measured and compared. 
Age group (Table 1) was found to have no 
effect on baseline CD4 count. Males were 
found to have started ART at a mean of 
3.4 years older than females, which is a 
significant difference (p<0.005). They also 
came to the clinics with more advanced 
disease than females, as indicated by CD4 
counts on average 59  cells/µL lower than 
those of females, also a significant difference 
(p<0.004).
Adverse outcomes: death, loss to 
follow-up, default and stopping 
treatment
A χ2 test showed that 28.6% of females 
and 33.8% of males had adverse outcomes. 
This difference does not have statistical 
significance (p>0.05). The findings were 
similar when multivariate logistic regression 
analysis was used, males being 1.3 times 
more likely to have an adverse outcome; 
again this was not significant (p=0.3).
While age was not found to affect the rate 
of adverse outcomes (p=0.973), a low CD4 
count was found to have a significant impact 
(p=0.025). However, when examining loss 
to follow-up as an adverse event on its own, 
the effects of CD4 count (p=0.609), age 
(p=0.722) and gender (p=0.985) were not 
found to be significant.
Treatment outcomes: retention 
in care, CD4 change and viral 
suppression
Of the 381 patients who started treatment in 
January - March 2007, 156 (40.9%) remained 
in care (Table 2). However, 109 (28.6%) of 
the 381 patients had been transferred out, 
so if these patients are considered as still in 
care, 69.5% remained in care. Removing trans-
ferred-out patients from the total of 381 leaves 
272 patients, giving a retention rate of 57.4%. 
Since we do not know how many transferred-
out patients were still on treatment, the latter 
figure is the most appropriate.
Looking only at the CD4 counts of the 
60  patients who had both baseline and 
6-month results, there was a significant 
change between the baseline and 6-month 
counts (Figs 1 and 2). The mean CD4 count 
at 6 months was 238 cells/µL, a significant 
rise of 112 cells/µL compared with baseline 
(p=0.000). There were gender differences 
in CD4 count, the rise for males being 
54  cells/ µL less than that for females; how-
ever, this difference was not statistically 
significant (p>0.005).
Patient age groups had varying influences 
on the CD4 count change from baseline to 
6 months. The 29 - 35-year age group had a 
Table 1. Baseline characteristics of the 
study subjects*
Characteristic
Gender, n/N (%)
Females 251/381 (65.8)
Males 130/381 (34.1)
Age (years), median 
(IQR)
35 (50)
Age categories (years), 
n/N (%)
0 - 28 90/368 (23.8)
29 - 35 96/368 (25.4)
36 - 42 95/368 (25.1)
>42 87/368 (22.8)
CD4 count (cells/µL), 
mean 
159
CD4 category (cells/µL), 
n/N (%) 
0 - 100 80/199 (40.2)
100 - 150 34/199 (17.1)
>150 85/199 (42.7)
IQR = interquartile range.
*Not all information was available for all the subjects.
Table 2. Treatment outcomes after  
60 months on treatment (N=381) 
Outcome n (%)
Active 156 (40.9)
Died 15 (3.9)
Defaulted 19 (5.0)
Lost to follow-up 76 (19.9)
Stopped ART 6 (1.6)
Transferred out 109 (28.6)
Baseline 6 months 60 months
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Fig. 1. Change in mean CD4 cell count over 60 months.
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greater CD4 count increase than the other 
age groups, while patients aged >42 years had 
a lower increase than the other age groups. 
Patients who had a relatively high baseline 
CD4 count tended to have a bigger CD4 
count change at 6 months than other patients.
Only 29 patients had both baseline and 
60-month CD4 counts. Age, gender and 
baseline CD4 count did not significantly 
influence the CD4 count change at 60 months. 
The mean CD4 count at 60  months was 
significantly better than that at baseline, with 
a mean of 447 cells/µL (p=0.000), i.e. a rise of 
288 cells/µL from baseline (measuring records 
that had both baseline and 60-month results).
Only 79 records had VL results for 6 
months and 49 VL results for 60 months. 
Gender and age did not influence VL 
outcomes at either 6 or 60 months. VL 
outcomes at 6 months were poor, with 
74.0% of patients achieving suppression to 
<400  copies/mL, compared with 91.0% at 
60 months (Fig. 3).
Discussion
Our findings indicate that there needs to be 
focus on a strategy to improve the quality 
of SA’s ART programme, and thereby ART 
programme outcomes.
We found that demographic characteristics 
did not contribute to adverse treatment out-
comes. Other studies have previously identi-
fied gender and/or age as having an association 
with adverse outcomes.[11,12] However, our 
findings are in agreement with those of 
another study, conducted in Johannesburg, 
that also found no associations between 
patient demographics and loss to follow-up. [13] 
In the current study only CD4 count had a 
significant association with adverse outcomes 
combined, which was not the case when loss 
to follow-up was analysed alone. This means 
that CD4 count is specifically associated 
with death on ART, which has also been 
established in other studies.[1]
Our mortality rate of 5.0% after 60 
months on HAART is lower than in previ-
ous studies, which have reported 6 - 11% 
mortality rates at 24 - 36 months. [1,4,11] 
Mortality rates may not be accurate, 
however, as previous findings have revealed 
that some patients who are recorded as lost 
to follow-up are in fact dead. While the 
improvements in CD4 counts at the start of 
treatment indicate that our mortality rate 
may not necessarily be inaccurate, tracing 
of patients who have been lost to follow-up 
would provide a more accurate rate.
The National Strategic Plan of 2012 - 2016[6] 
stipulates that the retention rate of patients 
on ART should be at least 80%. Our results 
show that the programme is currently not 
retaining more than 60% of patients after 5 
years on treatment. Various factors play a 
role in poor reten tion, the major influence 
in our study being patients who are lost to 
follow-up. These findings differ from those 
of a 4-year study in Johannes burg,[14] which 
showed a retention rate of 74%, while other 
studies in SA and in other African countries 
have shown rates of 60 - 70%.[1,4,10,13]
To evaluate the impact of ART on the 
immune system, we compared CD4 counts 
before and after exposure to treatment. 
The changes observed can be attributed to 
the ART programme alone, as CD4 counts 
have never been shown to improve on their 
own without treatment. Since a low CD4 
count is associated with mortality, the ART 
programme therefore has a high impact in 
reducing HIV-related mortality.
Females had higher baseline CD4 counts 
than males, and they had a significantly higher 
CD4 count increase at 6 months. Other studies 
have also established that males have lower 
CD4 counts, both at baseline and during 
therapy.[14,15] There have been many suggestions 
as to why this should be so, such as males 
starting treatment later than females, together 
with biological and sociocultural factors.[2,14]
We also found that patients who started 
treatment with a relatively high CD4 count 
had a greater rise in CD4 count at 6 months. 
The SA ART initiation eligibility criteria have 
recently changed to a CD4 count of 350 instead 
of 200 cells/µL, so CD4 count increases are 
likely to be much higher in the future.
Study limitations
Our study had a number of limitations. 
Firstly, we analysed data that had already 
been collected as routine data. There were lots 
of missing data, which had a serious impact 
on the analysis of measurements such as CD4 
count and VL. It was therefore difficult to 
analyse these measurements at intervals of 12, 
24, 36 and 48 months, as had initially been 
intended. Secondly, we could not do further 
follow-up on whether the causes of reported 
deaths were HIV related or not. Thirdly, 
because of time constraints we could not trace 
at least a sample of those lost to follow-up, 
to establish whether they were still alive and 
obtaining treatment elsewhere, or had died.
Conclusions
The findings of this study have revealed 
important health systems-related issues 
that need to be strengthened in order to 
improve the outcomes of the national ART 
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programme. According to the WHO, the health information system 
is one of the six health systems building blocks.[15] Poor data quality 
has a negative impact on the routine monitoring of the programme, 
on patient management and follow-up, and even on programme 
evaluation. It is important to have an efficient, up-to-date health 
information system for this programme in order to improve research 
output, both for students and for researchers.
Proper records of patient transfers to other facilities are important, 
and more important are ways to find out whether patients do in fact 
report to the facilities they are transferred to. Doing so will limit the 
uncertainty experienced in classifying transferred-out patients as still 
alive and on treatment.
The study showed that the ART programme has managed to 
maintain high VL suppression and to improve immunity in patients 
who are immunocompromised. Both these responses indicate that the 
programme is successful.[4,5] Further studies that follow each patient 
reported as lost to follow-up are recommended. Strengthening of 
patient support and tracing is likely to reduce the number of such 
patients. Proper data quality management will improve the monitoring 
of care, and thereby also the programme outputs and outcomes.
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